Rapid Drug Development
Provide Better Insights.
Identify Drug Candidates.
Shorten Development Time.
Drug development can be a lengthy and costly process and many new drug candidates fail during clinical trials. Many new drugs present a mixed picture of efficacy and toxicity, making development decisions difficult. Population PK/PD analysis allows for more efficient use of clinical trial results for decision making in several ways. The use of these methods allows more rapid identification of appropriate dose regimens so fewer clinical trials are needed. The ability to make timely and well informed development decisions translates to major cost savings.
What We Do
Population Pharmacokinetic (PK) & Pharmacodynamic (PD) models
Projections Research, Inc. uses population pharmacokinetic (PK) and pharmacodynamic (PD) models to describe the time course of individual patient exposure and response to a new treatment. PK is the study of how the body processes a drug and PD is the study of how the drug acts on the body. Population PK/PD models are used to determine how patient factors such as demographics, disease status and progression, and co-medications, might affect patient exposure to drug and their subsequent response. The models can be used to simulate different dose regimens and treatment options. The simulation results can then help design more informative and robust clinical studies.